Preparation and Evaluation of a Self-Emulsifying Drug Delivery System for Improving the Solubility and Permeability of Ticagrelor

Anam Aziz,Muhammad Zaman,Mahtab Ahmad Khan,Talha Jamshaid,Muhammad Hammad Butt,Huma Hameed,Muhammad Shafeeq Ur Rahman,Qurat-ul-Ain Shoaib
DOI: https://doi.org/10.1021/acsomega.3c08700
IF: 4.1
2024-03-12
ACS Omega
Abstract:Ticagrelor (TCG) is a BCS class IV antiplatelet drug used to prevent platelet aggregation in patients with acute coronary syndrome, having poor solubility and permeability. The goal of this study was to develop a self-nanoemulsifying drug delivery system (SNEDDS) of TCG to improve its solubility and permeability. The excipients were selected based on the maximum solubility of TCG and observed by UV spectrophotometer. Different combinations of oil, surfactant, and co-surfactant (1:1, 2:1, and...
chemistry, multidisciplinary
What problem does this paper attempt to address?
The main objective of this paper is to address the solubility and permeability issues of Ticagrelor (TCG), a Biopharmaceutics Classification System (BCS) Class IV antiplatelet drug. Ticagrelor is used to prevent platelet aggregation in patients with acute coronary syndrome, but its oral bioavailability is limited due to its low solubility in water and intestinal membrane permeability. To solve this problem, the research team developed a Self-Nanoemulsifying Drug Delivery System (SNEDDS) to enhance the solubility and permeability of Ticagrelor. By selecting excipients that provide maximum solubility for Ticagrelor and using pseudo-ternary phase diagrams to determine the optimal ratios of oil, surfactant, and co-surfactant, the researchers prepared various SNEDDS formulations. These SNEDDS formulations underwent a series of evaluations, including particle size, polydispersity index (PDI), ζ-potential, self-emulsification ability, cloud point determination, thermodynamic stability studies, and encapsulation efficiency. Additionally, in vitro release experiments, transdermal experiments, and pharmacodynamic studies were conducted to assess the performance improvement of the optimized Ticagrelor SNEDDS formulations compared to the pure drug suspension. The results showed that the SNEDDS formulations significantly improved the solubility and permeability of Ticagrelor. In in vitro release experiments, the selected SNEDDS formulations (such as F4 and F6) achieved drug release rates of approximately 98.45% and 97.86% in 0.1N HCl and pH 6.8 phosphate buffer, respectively, far higher than the 28.05% of the pure drug suspension. Transdermal experiments indicated that the apparent permeability coefficient of the F4 formulation was about 4 times higher than that of the pure drug suspension. Pharmacodynamic studies further confirmed that the Ticagrelor SNEDDS F4 formulation exhibited enhanced antiplatelet activity in rabbits compared to the pure drug suspension. In conclusion, this study demonstrates that Ticagrelor SNEDDS can serve as an effective means to enhance its antiplatelet activity by improving its solubility and permeability.